Thermo Fisher Scientific | TMO - Ebitda


Thermo Fisher Scientific reported $2.7B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Abbott USD 3.27B 178M Dec/2025
Agilent USD 456M 84M Dec/2025
Becton, Dickinson and Co. USD 1.71B 433M Dec/2025
Bio Techne USD 116.71M 13.29M Mar/2026
Bio-Rad Laboratories USD 983.8M 1.36B Dec/2025
Boston Scientific USD 1.16B 213M Dec/2025
Bruker USD 110M 101.6M Mar/2026
Charles River Laboratories USD 229.8M 28.26M Mar/2026
Danaher USD 1.92B 204M Mar/2026
Dentsply International USD 129M 6M Mar/2026
Edwards Lifesciences USD 70.1M 394.2M Dec/2025
General Electric Aerospace USD 2.84B 568M Mar/2026
Henry Schein USD 289M 2M Mar/2026
Illumina USD 469M 137M Dec/2025
Intuitive Surgical USD 1.09B 165.5M Dec/2025
IQVIA Holdings USD 932M 114M Mar/2026
Laboratory Of America USD 605.6M 17.5M Mar/2026
Medtronic USD 2.81B 119M Mar/2026
Mettler Toledo International USD 278.99M 100.24M Mar/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Olympus JPY 43.41B 2.31B Mar/2026
OraSure Technologies USD -17.7M 4.06M Dec/2025
Quest Diagnostics USD 557M 20M Mar/2026
Repligen USD 40.01M 469K Mar/2026
Revvity USD 272.91M 24M Mar/2026
Stryker USD 1.57B 618M Mar/2026
Thermo Fisher Scientific USD 2.7B 464M Mar/2026
Veracyte USD 42.8M 488K Mar/2026
Waters USD 380.97M 85.83M Dec/2025
Zimmer Biomet Holdings USD 759M 120.8M Dec/2025